We protect your health through science
Investigation
AIDS Immunopathology
Publications
Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals JOURNAL OF CLINICAL MEDICINE.
Molina-Carrion, Silvia; Brochado-Kith, Oscar; Gonzalez-Garcia, Juan; et al; Jimenez-Sousa, Maria Angeles. (12/12). 2020. Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals JOURNAL OF CLINICAL MEDICINE. 9. ISSN 2077-0383. https://doi.org/10.3390/jcm9082407.
Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respiration. 2018 Jul
Alastruey-Izquierdo A, Cadranel J, Flick H, Godet C, Hennequin C, Hoenigl M, Kosmidis C, Lange C, Munteanu O, Page I, Salzer HJF; on behalf of CPAnet. Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respiration. 2018 Jul 6:1-12. doi: 10.1159/000489474. [Epub ahead of print] Review. PMID: 29982245.
PUBMED DOIThe Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. Open Forum Infect Dis. 2019 Dec
Samayoa B, Aguirre L, Bonilla O, Medina N, Lau-Bonilla D, Mercado D, Moller A, Perez JC, Alastruey-Izquierdo A, Arathoon E, Denning DW, Rodríguez-Tudela JL; “Fungired”. The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. Open Forum Infect Dis. 2019 Dec 15;7(1):ofz534. doi: 10.1093/ofid/ofz534. PMID: 31915715.
PUBMED DOIFungired. Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. AIDS. 2020 Sep 1
Medina N, Alastruey-Izquierdo A, Mercado D, Bonilla O, Pérez JC, Aguirre L, Samayoa B, Arathoon E, Denning DW, Rodriguez-Tudela JL; Fungired. Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. AIDS. 2020 Sep 1;34(11):1625-1632. doi: 10.1097/QAD.0000000000002631. PMID: 32694415.
PUBMED DOIPopulation-Based Program of filamentous fungi and Antifungal Resistance in Spain (FILPOP STUDY). Antimicrob Agents Chemother. 2013 Jul
Ana Alastruey-Izquierdo*, Emilia Mellado, Teresa Pelaez, Javier Pemán, Soledad Zapico, María Álvarez, Juan L Rodriguez-Tudela, Manuel Cuenca-Estrella Population-Based Program of filamentous fungi and Antifungal Resistance in Spain (FILPOP STUDY). Antimicrob Agents Chemother. 2013 Jul;57(7):3380-7. doi: 10.1128/AAC.01287-13. PMID: 28319466
PUBMED DOIThe global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017 Dec
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017 Dec;17(12. doi: 10.1016/S1473-3099(17)30316-X. PMID: 28774698.
PUBMED DOISequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes.
Vega Y, Delgado E, de la Barrera J, Carrera C, Zaballos Á, Cuesta I, Mariño A, Ocampo A, Miralles C, Pérez-Castro S, Álvarez H, López-Miragaya I, García-Bodas E, Díez-Fuertes F, Thomson MM. Sequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes. PLoS One. 2016 Jun 29;11(6):e0158525.
PUBMED DOIY155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors
Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, Molinero M, Lopez-Miragaya I, Rey S, Cañizares A, Rodriguez G, Gonzalez-Velasco C, Lackenby A, Casas I. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro Surveill. 2014 Jul 10;19(27):14-20.
PUBMED DOIComparison of two highly discriminatory typing methods to analyze Aspergillus fumigatus azole resistance
Garcia-Rubio R, Escribano P, Gomez A, Guinea J, and Mellado E. Comparison of two highly discriminatory typing methods to analyze Aspergillus fumigatus azole resistance. Frontiers in Microbiology 2018. Jul 20;9:1626.
PUBMED DOIEvaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia.
Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Clin Microbiol Infect. 2017 Jan; 23(1):49.e1-49.e8.
PUBMED DOIDevelopment and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.
Bernal-Martínez L, Gil H, Rivero-Menéndez O, Gago S, Cuenca-Estrella M, Mellado E, Alastruey-Izquierdo A. Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01083-17.
PUBMED DOICervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS.
Nebreda T, Andres AG, Fuentes S, Calleja R, Jimenez MS. Cervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS. New Microbes and New Infections .2018. March 22:1-3.
PUBMED DOIIn-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain.
Sagasta S, Millan-Lou MI, Jiménez MS, Martin C, Samper S. In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain. Tuberculosis. 2016. Sep. 100:46-52.
PUBMED DOIGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016;60(1):6-13.
PUBMED DOICharacterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin
Garcia-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, et al. Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. J Gen Virol. 2014;95(Pt 5):1033-42.
PUBMED DOIEpidemic history of hepatitis C virus genotypes and subtypes in Portugal.
Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Tato Marinho R, Borrego P, Taveira N. 2018. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018; 8:12266. (A; FI= 4.12; Q1 Multidisciplinary Sciences; DOI:10.1038/s41598-018-30528-0).
PUBMED DOILow frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Morón S, Jiménez-Sousa MA, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep. 2017; 7(1):2892. (A; FI= 4.12; Q1 Multidisciplinary Sciences).
PUBMED DOIPlasma miRNA profile at COVID-19 onset predicts severity status and mortality.
Fernández-Pato A; Virseda-Berdices A, Ryan P; Martínez-González O, Peréz-García F, Resino S, Martin-Vicente M, Valle-Millares D, Brochado-Kith O; Blancas R; Ceballos FC; Bartolome-Sánchez S; Vidal-Alcántara EJ; Alonso-Menchén D, Blanca-López N; Ramirez Martinez-Acitores I, Rava M, Jiménez-Sousa MA (‡ *), Amanda Fernández-Rodríguez (‡ *). Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg Microbes Infect 2022; 11(1):676-688 (A; FI= 19.57; D1, Infectious Diseases; JCR 2021).
PUBMED DOIMild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.
García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020).
PUBMED DOIAdditional Information
The AIDS Immunopathology Unit has been coordinated since 2000 by Dr. José Alcamí, bringing together during its history more than 20 independent researchers who collaboratively study different aspects of HIV infection. During this years, more than 30 visiting researchers and more than 50 national and international students have passed through the unit. From the beginning of the year 2025, Javier García Pérez and Francisco Díez Fuertes assumed the coordination of the AIDS Immunopathology Unit, with the aim of projecting its scientific competitiveness following multidisciplinary approaches and through the maintenance of the current close collaborations, as well as the promotion of participation in new national and international research networks.
Historically, the current members of the unit have focused on different lines of basic research that include the study of antibodies and the development of vaccines against HIV-1, the study of viral entry and tropism of the virus or the study of the host through the genomic characterization of populations with an extreme phenotype. Currently, the activity of our unit in the field of HIV-1 is focused on three main lines:
1. Mecanismos moleculares asociados a la protección de la infección por VIH-1 en pacientes con distrofia muscular de cinturas dominante D2 (LGMDD2).
2. Generación de anticuerpos neutralizantes de uso terapéutico basados en la respuesta neutralizante de amplio espectro frente a virus fundadores.
3. Cribado y caracterización de nuevos fármacos anti-latencia frente al VIH-1.
A partir del año 2020, nuestra unidad se vuelca con la investigación sobre COVID-19, participando y liderando diferentes proyectos de investigación aplicada y clínica. Fruto de esta fuerte implicación en el campo, en la actualidad se mantienen diferentes estudios sobre la caracterización de la respuesta inmune frente a SARS-CoV-2, integrando diferentes técnicas de virología molecular, estrategias de inteligencia epidemiológica y tecnologías de célula única.
We also participate in different research consortiums and networks, such as the Spanish AIDS Research Network or the Center for Biomedical Research in Infectious Diseases Network (CIBER-INFEC), in which we participate as researchers in different lines and work packages within the research programs “Global Health, emerging and re-emerging infections” as well as “HIV/AIDS and sexually transmitted infections”.
Supervised doctoral theses
1. GENOMIC AND FUNCTIONAL ANALYSIS OF HIV-1 PROTECTION PARAMETERS IN PATIENTS WITH SLOW PROGRESSION OF INFECTION.
Student: Erick de la Torre Tarazona.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad Autónoma de Madrid.
Defense date: July 14th, 2020.
2. ANALYSIS OF MIARN EXPRESSION PROFILES AND FUNCTIONAL CHARACTERIZATION IN HIV-POSITIVE INDIVIDUALS WITH DIFFERENT PROGRESSION TO AIDS.
Student: Rubén Ayala Suárez.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad de Alcalá.
Defense date: June 12nd, 2023.
The AIDS Immunopathology Unit has been coordinated since 2000 by Dr. José Alcamí, bringing together during its history more than 20 independent researchers who collaboratively study different aspects of HIV infection. During this years, more than 30 visiting researchers and more than 50 national and international students have passed through the unit. From the beginning of the year 2025, Javier García Pérez and Francisco Díez Fuertes assumed the coordination of the AIDS Immunopathology Unit, with the aim of projecting its scientific competitiveness following multidisciplinary approaches and through the maintenance of the current close collaborations, as well as the promotion of participation in new national and international research networks.
Historically, the current members of the unit have focused on different lines of basic research that include the study of antibodies and the development of vaccines against HIV-1, the study of viral entry and tropism of the virus or the study of the host through the genomic characterization of populations with an extreme phenotype. Currently, the activity of our unit in the field of HIV-1 is focused on three main lines:
1. Mecanismos moleculares asociados a la protección de la infección por VIH-1 en pacientes con distrofia muscular de cinturas dominante D2 (LGMDD2).
2. Generación de anticuerpos neutralizantes de uso terapéutico basados en la respuesta neutralizante de amplio espectro frente a virus fundadores.
3. Cribado y caracterización de nuevos fármacos anti-latencia frente al VIH-1.
A partir del año 2020, nuestra unidad se vuelca con la investigación sobre COVID-19, participando y liderando diferentes proyectos de investigación aplicada y clínica. Fruto de esta fuerte implicación en el campo, en la actualidad se mantienen diferentes estudios sobre la caracterización de la respuesta inmune frente a SARS-CoV-2, integrando diferentes técnicas de virología molecular, estrategias de inteligencia epidemiológica y tecnologías de célula única.
We also participate in different research consortiums and networks, such as the Spanish AIDS Research Network or the Center for Biomedical Research in Infectious Diseases Network (CIBER-INFEC), in which we participate as researchers in different lines and work packages within the research programs “Global Health, emerging and re-emerging infections” as well as “HIV/AIDS and sexually transmitted infections”.
Supervised doctoral theses
1. GENOMIC AND FUNCTIONAL ANALYSIS OF HIV-1 PROTECTION PARAMETERS IN PATIENTS WITH SLOW PROGRESSION OF INFECTION.
Student: Erick de la Torre Tarazona.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad Autónoma de Madrid.
Defense date: July 14th, 2020.
2. ANALYSIS OF MIARN EXPRESSION PROFILES AND FUNCTIONAL CHARACTERIZATION IN HIV-POSITIVE INDIVIDUALS WITH DIFFERENT PROGRESSION TO AIDS.
Student: Rubén Ayala Suárez.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad de Alcalá.
Defense date: June 12nd, 2023.